Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies
The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standar...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1204722/full |
| _version_ | 1797787535273885696 |
|---|---|
| author | Ram Kumar Sahu Sakina Ruhi Ashok Kumar Jeppu Husni Ahmed Al-Goshae Ayesha Syed Sanjay Nagdev Retno Widyowati Wiwied Ekasari Jiyauddin Khan Bedanta Bhattacharjee Manoj Goyal Sankha Bhattacharya Rajendra K. Jangde |
| author_facet | Ram Kumar Sahu Sakina Ruhi Ashok Kumar Jeppu Husni Ahmed Al-Goshae Ayesha Syed Sanjay Nagdev Retno Widyowati Wiwied Ekasari Jiyauddin Khan Bedanta Bhattacharjee Manoj Goyal Sankha Bhattacharya Rajendra K. Jangde |
| author_sort | Ram Kumar Sahu |
| collection | DOAJ |
| description | The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standard treatments. In mesothelioma, the predominant pattern of lesions is a loss of genes that limit tumour growth. Despite the worldwide ban on the manufacture and supply of asbestos, the prevalence of mesothelioma continues to increase. Mesothelioma presents and behaves in a variety of ways, making diagnosis challenging. Most treatments available today for MM are ineffective, and the median life expectancy is between 10 and 12 months. However, in recent years, considerable progress has already been made in understanding the genetics and molecular pathophysiology of mesothelioma by addressing hippo signaling pathway. The development and progression of MM are related to many important genetic alterations. This is related to NF2 and/or LATS2 mutations that activate the transcriptional coactivator YAP. The X-rays, CT scans, MRIs, and PET scans are used to diagnose the MM. The MM are treated with surgery, chemotherapy, first-line combination chemotherapy, second-line treatment, radiation therapy, adoptive T-cell treatment, targeted therapy, and cancer vaccines. Recent clinical trials investigating the function of surgery have led to the development of innovative approaches to the treatment of associated pleural effusions as well as the introduction of targeted medications. An interdisciplinary collaborative approach is needed for the effective care of persons who have mesothelioma because of the rising intricacy of mesothelioma treatment. This article highlights the key findings in the molecular pathogenesis of mesothelioma, diagnosis with special emphasis on the management of mesothelioma. |
| first_indexed | 2024-03-13T01:24:16Z |
| format | Article |
| id | doaj.art-6e1a1fdd1d1e47a0855cd1fe6c01cd86 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-13T01:24:16Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-6e1a1fdd1d1e47a0855cd1fe6c01cd862023-07-04T17:16:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-07-011310.3389/fonc.2023.12047221204722Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studiesRam Kumar Sahu0Sakina Ruhi1Ashok Kumar Jeppu2Husni Ahmed Al-Goshae3Ayesha Syed4Sanjay Nagdev5Retno Widyowati6Wiwied Ekasari7Jiyauddin Khan8Bedanta Bhattacharjee9Manoj Goyal10Sankha Bhattacharya11Rajendra K. Jangde12Department of Pharmaceutical Sciences, Hemvati Nandan Bahuguna Garhwal University (A Central University), Chauras, Tehri Garhwal, Uttarakhand, IndiaDepartment of Biochemistry, International Medical School (IMS), Management and Science University, Shah Alam, Selangor, MalaysiaDepartment of Biochemistry, International Medical School (IMS), Management and Science University, Shah Alam, Selangor, MalaysiaDepartment of Anantomy, International Medical School (IMS), Management and Science University, Shah Alam, Selangor, MalaysiaDepartment of Anatomy, Physiology, and Biochemistry, Management and Science University, Shah Alam, Selangor, MalaysiaDepartment of Pharmacy, Gyan Ganga Institute of Technology and Sciences, Jabalpur, Madhya Pradesh, IndiaDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, IndonesiaDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, IndonesiaSchool of Pharmacy, Management and Science University, Shah Alam, Selangor, MalaysiaGirijananda Chowdhury Institute of Pharmaceutical Science, Tezpur, Assam, IndiaDepartment of Pharmaceutical Sciences, Hemvati Nandan Bahuguna Garhwal University (A Central University), Chauras, Tehri Garhwal, Uttarakhand, IndiaSchool of Pharmacy & Technology Management, SVKM’s NMIMS, Shirpur, MH, India0University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, IndiaThe pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standard treatments. In mesothelioma, the predominant pattern of lesions is a loss of genes that limit tumour growth. Despite the worldwide ban on the manufacture and supply of asbestos, the prevalence of mesothelioma continues to increase. Mesothelioma presents and behaves in a variety of ways, making diagnosis challenging. Most treatments available today for MM are ineffective, and the median life expectancy is between 10 and 12 months. However, in recent years, considerable progress has already been made in understanding the genetics and molecular pathophysiology of mesothelioma by addressing hippo signaling pathway. The development and progression of MM are related to many important genetic alterations. This is related to NF2 and/or LATS2 mutations that activate the transcriptional coactivator YAP. The X-rays, CT scans, MRIs, and PET scans are used to diagnose the MM. The MM are treated with surgery, chemotherapy, first-line combination chemotherapy, second-line treatment, radiation therapy, adoptive T-cell treatment, targeted therapy, and cancer vaccines. Recent clinical trials investigating the function of surgery have led to the development of innovative approaches to the treatment of associated pleural effusions as well as the introduction of targeted medications. An interdisciplinary collaborative approach is needed for the effective care of persons who have mesothelioma because of the rising intricacy of mesothelioma treatment. This article highlights the key findings in the molecular pathogenesis of mesothelioma, diagnosis with special emphasis on the management of mesothelioma.https://www.frontiersin.org/articles/10.3389/fonc.2023.1204722/fullmesotheliomaasbestosSV40biomarkershippo signaling pathway |
| spellingShingle | Ram Kumar Sahu Sakina Ruhi Ashok Kumar Jeppu Husni Ahmed Al-Goshae Ayesha Syed Sanjay Nagdev Retno Widyowati Wiwied Ekasari Jiyauddin Khan Bedanta Bhattacharjee Manoj Goyal Sankha Bhattacharya Rajendra K. Jangde Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies Frontiers in Oncology mesothelioma asbestos SV40 biomarkers hippo signaling pathway |
| title | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
| title_full | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
| title_fullStr | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
| title_full_unstemmed | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
| title_short | Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies |
| title_sort | malignant mesothelioma tumours molecular pathogenesis diagnosis and therapies accompanying clinical studies |
| topic | mesothelioma asbestos SV40 biomarkers hippo signaling pathway |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1204722/full |
| work_keys_str_mv | AT ramkumarsahu malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT sakinaruhi malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT ashokkumarjeppu malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT husniahmedalgoshae malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT ayeshasyed malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT sanjaynagdev malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT retnowidyowati malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT wiwiedekasari malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT jiyauddinkhan malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT bedantabhattacharjee malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT manojgoyal malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT sankhabhattacharya malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies AT rajendrakjangde malignantmesotheliomatumoursmolecularpathogenesisdiagnosisandtherapiesaccompanyingclinicalstudies |